Skip to main content

Zerlasiran

Home / Our Pipeline / Zerlasiran

Addressing a Major Unmet Need in Cardiovascular Disease

Zerlasiran is our wholly owned siRNA (short interfering RNA) in development for high lipoprotein(a), or Lp(a), a genetically determined cardiovascular risk factor affecting around 20% of the world’s population.

About SLN360

Zerlasiran is a gene ‘silencing’ therapy – one that is designed to temporarily block a specific gene’s message that would otherwise trigger an unwanted effect. In this case, it aims to ‘silence’ LPA, a gene that tells the body to make a specific protein that is only found in Lp(a). By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks and strokes.

Learn More About Cardiovascular Disease Due to High Lp(a)

apoll

Phase 1 Study to Investigate Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of Zerlasiran (SLN360) in Subjects With Elevated Lipoprotein(a)

Learn More

apoll

Phase 2 Study to Evaluate Zerlasiran (SLN360) in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Learn More

Lead investigator of the zerlasiran APOLLO trial, Steven E. Nissen, M.D., Chief Academic Officer of the Heart, Vascular and Thoracic Institute at Cleveland Clinic, discusses high lipoprotein(a) as a key driver of heart disease and encouraging results observed in the zerlasiran phase 1 single-ascending dose study.